{"analyses":[{"ciLowerLimit":"-19.15","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-2.48","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0113","paramType":"Least Squares Mean Difference","paramValue":"-10.82","statisticalMethod":"MMRM"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.35","value":"-14.34"},{"groupId":"OG001","spread":"3.65","value":"-3.52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is comprised of 5 functional scales (physical, role, emotional, social, cognitive), eight single item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, dyspnea), as well as sub-scales assessing global health/quality of life and financial impact. Most items use a 4-point Likert scale from \"not at all\" to \"very much\" and a one-week recall period with the exception of the final two items which use a 7 point scale response from \"very poor\" to \"excellent\". Scores were averaged and transformed to a 0-100 scale, with higher scores representing better functioning/quality of life. An increase in scores from Baseline indicated an improved functioning/quality of life, and a decrease in scores from Baseline indicated a worsened functioning/quality of life. Baseline was the last assessment done before or on the day of first dose date. Change from Baseline was defined as the post-Baseline value minus Baseline value.","dispersionType":"Standard Error","groups":[{"description":"Participants were randomized to receive 200 milligrams (mg) of MMB orally QD and a DAN-placebo orally twice daily (BID) during the randomized 24-week double-blind treatment period. Participants who completed the randomized treatment period or discontinued treatment early for other reasons but completed scheduled assessments through Week 24 were enrolled in an open-label extended treatment period. Participants continued to receive 200 mg of MMB orally QD during the open-label extended treatment period. Participants who discontinued treatment prior to Week 24 due to splenic progression or other reasons, but completed assessments, were unblinded. Participants who discontinued MMB during the randomized treatment period were not eligible to receive MMB in the open-label extended treatment period. Participants who were randomized to MMB during the randomized treatment period with confirmed splenic progression could not proceed to the open-label extended treatment period.","id":"OG000","title":"MMB 200 mg QD + Placebo"},{"description":"Participants were randomized to receive 300 mg of DAN orally BID and MMB-placebo orally QD during the randomized 24-week double-blind treatment period. Participants who completed the randomized treatment period, discontinued treatment early due to splenic progression, or discontinued treatment early for other reasons but completed scheduled assessments through Week 24 were enrolled in an open-label extended treatment period. Participants who received DAN 300 mg BID during randomized period switched to receive 200 mg of MMB orally QD during open-label extended treatment period.","id":"OG001","title":"DAN 300 mg BID + Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT Analysis Set. Only those participants with data available at specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 24","title":"Change From Baseline in Cancer-related Fatigue as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at Week 24","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}